CryoPort Inc. (CYRX)
CYRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1124524/000110465926024180/0001104659-26-024180-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CYRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001124524 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $176.2M |
| Net income | $78.3M |
| Operating income | -$36.8M |
| Net margin | 44.4% |
| Operating margin | -20.9% |
| Revenue growth | +12.4% |
| Cash | $250.5M |
| Total assets | $765.0M |
| P/E (computed) | 12.8× |
| P/S (computed) | 5.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $279.2M cash; operating cash flow $2.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 50,700,429 (2026-10-30); 50,068,904 a year earlier; 48,963,717 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Nashville, Tennessee, United States | PCAOB Form AP 2026-03-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $50.2M | -$10.9M | $5.2M | $279.2M | $186.1M | $192.4M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $49.0M | -$8.3M | $1.1M | $269.3M | $185.8M | $186.5M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $47.8M | -$10.5M | $3.7M | $272.9M | $185.5M | $182.9M | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $45.5M | -$11.6M | $919K | $250.5M | $185.3M | $176.2M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $44.2M | -$6.9M | $2.2M | $255.8M | $184.8M | $172.2M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $45.5M | $108.9M | -$7.3M | $243.4M | $184.5M | $166.3M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $41.0M | -$12.0M | -$4.3M | $36.1M | $198.7M | $160.5M | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $41.5M | -$18.7M | -$5.5M | $34.1M | $198.4M | $156.8M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2023-12-21 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.1% |
| 1 month | +17.3% |
| 3 months | +31.5% |
| Year to date | +107.2% |
| 1 year | +127.1% |
| From 52-week high | -4.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MLTX | MoonLake Immunotherapeutics | $11.73 | -6.16% | $998.3M |
| SVRA | Savara Inc. | $4.46 | -3.77% | $985.1M |
| SPTX | Seaport Therapeutics Inc. | $19.12 | -4.30% | $1.0B |
| JBIO | Jade Biosciences Inc. | $15.34 | -4.99% | $975.3M |
| VSTM | Verastem Inc. | $7.70 | -5.87% | $970.3M |
| MTRI | Mentari Therapeutics Inc. | $19.87 | +6.83% | $1.0B |
| ANRO | Alto Neuroscience Inc. | $27.12 | -8.19% | $1.1B |
| HROW | Harrow Inc. | $29.09 | -3.42% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier